Literature DB >> 15931631

Bloodstream infection after umbilical cord blood transplantation using reduced-intensity stem cell transplantation for adult patients.

Hiroto Narimatsu1, Tomoko Matsumura, Masahiro Kami, Shigesaburo Miyakoshi, Eiji Kusumi, Shinsuke Takagi, Yuji Miura, Daisuke Kato, Chiho Inokuchi, Tomohiro Myojo, Yukiko Kishi, Naoko Murashige, Koichiro Yuji, Kazuhiro Masuoka, Akiko Yoneyama, Atsushi Wake, Shinichi Morinaga, Yoshinobu Kanda, Shuichi Taniguchi.   

Abstract

Bloodstream infection (BSI) is a significant problem after cord blood transplantation (CBT). However, little information has been reported on BSI after reduced-intensity CBT (RI-CBT). We retrospectively reviewed the medical records of 102 patients. The median age of the patients was 55 years (range, 17-79 years). Preparative regimens comprised fludarabine 125 to 150 mg/m 2 , melphalan 80 to 140 mg/m 2 , or busulfan 8 mg/kg and total body irradiation 2 to 8 Gy. Prophylaxis against graft-versus-host disease comprised cyclosporin or tacrolimus. BSI developed within 100 days of RI-CBT in 32 patients. The cumulative incidence of BSI was 25% at day 30 and 32% at day 100. The median onset was day 15 (range, 1-98 days). Causative organisms included Pseudomonas aeruginosa (n = 12), Staphylococcus epidermidis (n = 11), Staphylococcus aureus (n = 6), Enterococcus faecium (n = 4), Enterococcus faecalis (n = 4), Stenotrophomonas maltophilia (n = 4), and others (n = 7). Of the 32 patients with BSI, 25 (84%) died within 100 days after RI-CBT. BSI was the direct cause of death in 8 patients (25%). Univariate analysis failed to identify any significant risk factors. BSI clearly represents a significant and fatal complication after RI-CBT. Further studies are warranted to determine clinical characteristics, identify patients at high risk of BSI, and establish therapeutic strategies.

Entities:  

Mesh:

Year:  2005        PMID: 15931631     DOI: 10.1016/j.bbmt.2005.01.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  10 in total

1.  Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Authors:  B L Tang; X Y Zhu; C C Zheng; H L Liu; L Q Geng; X B Wang; K Y Ding; W Yao; J Tong; K D Song; L Zhang; P Qiang; Z M Sun
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Colistin is relatively safe in hematological malignancies and hematopoietic stem cell transplantation patients.

Authors:  D Averbuch; E Horwitz; J Strahilevitz; P Stepensky; N Goldschmidt; M E Gatt; M Y Shapira; I B Resnick; D Engelhard
Journal:  Infection       Date:  2013-05-08       Impact factor: 3.553

3.  Pretransplant serum ferritin is associated with bloodstream infections within 100 days of allogeneic stem cell transplantation for myeloid malignancies.

Authors:  Takayoshi Tachibana; Masatsugu Tanaka; Hirotaka Takasaki; Ayumi Numata; Satomi Ito; Reina Watanabe; Rie Hyo; Rika Ohshima; Maki Hagihara; Rika Sakai; Shin Fujisawa; Naoto Tomita; Hiroyuki Fujita; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2011-02-18       Impact factor: 2.490

4.  Reduced mortality after allogeneic hematopoietic-cell transplantation.

Authors:  Ted A Gooley; Jason W Chien; Steven A Pergam; Sangeeta Hingorani; Mohamed L Sorror; Michael Boeckh; Paul J Martin; Brenda M Sandmaier; Kieren A Marr; Frederick R Appelbaum; Rainer Storb; George B McDonald
Journal:  N Engl J Med       Date:  2010-11-25       Impact factor: 91.245

5.  Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).

Authors:  Diana Averbuch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Christina Orasch; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

6.  Bacterial bloodstream infection in neutropenic adult patients after myeloablative cord blood transplantation: experience of a single institution in Japan.

Authors:  Akira Tomonari; Satoshi Takahashi; Jun Ooi; Nobuhiro Tsukada; Takaaki Konuma; Takeshi Kobayashi; Aki Sato; Kashiya Takasugi; Tohru Iseki; Arinobu Tojo; Shigetaka Asano
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

7.  Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience.

Authors:  M Yilmaz; R F Chemaly; X Y Han; P F Thall; P S Fox; J J Tarrand; M J De Lima; C M Hosing; U R Popat; E Shpall; R E Champlin; M H Qazilbash
Journal:  Bone Marrow Transplant       Date:  2013-03-18       Impact factor: 5.483

Review 8.  Infectious Complications after Umbilical Cord-Blood Transplantation from Unrelated Donors.

Authors:  Juan Montoro; José Luis Piñana; Federico Moscardó; Jaime Sanz
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-10-18       Impact factor: 2.576

9.  The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients.

Authors:  Mücahit Yemişen; İlker İnanç Balkan; Ayşe Salihoğlu; Ahmet Emre Eşkazan; Bilgül Mete; M Cem Ar; Şeniz Öngören; Zafer Başlar; Reşat Özaras; Neşe Saltoğlu; Ali Mert; Burhan Ferhanoğlu; Recep Öztürk; Fehmi Tabak; Teoman Soysal
Journal:  Turk J Haematol       Date:  2015-05-04       Impact factor: 1.831

10.  Microbiology and Risk Factors for Hospital-Associated Bloodstream Infections Among Pediatric Hematopoietic Stem Cell Transplant Recipients.

Authors:  Ibukunoluwa C Akinboyo; Rebecca R Young; Lisa P Spees; Sarah M Heston; Michael J Smith; Yeh-Chung Chang; Lauren E McGill; Paul L Martin; Kirsten Jenkins; Debra J Lugo; Kevin C Hazen; Patrick C Seed; Matthew S Kelly
Journal:  Open Forum Infect Dis       Date:  2020-03-16       Impact factor: 3.835

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.